Brain 'death switch' linked to Alzheimer's progression could be blocked by FP802
Researchers at Heidelberg and Shandong University identified a toxic interaction between NMDA receptors and the TRPM4 channel—described as a 'death complex'—that worsens Alzheimer’s in a mouse model. They showed FP802, a novel neuroprotective drug, can block this interaction, slowing neurodegeneration, preserving synapses and mitochondria, and reducing amyloid deposits, offering a therapeutic approach distinct from amyloid removal. While promising, further pharmacological development, toxicology work, and clinical trials are needed before it could be used in humans, and researchers are also exploring potential ALS applications.
